Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains

Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?

Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.

Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy

Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.

3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan

The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.

FDA classifies recall of Medtronic embolization devices as 'most serious'

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.